Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals (KNSA) disclosed a Form 4 showing its Chief Medical Officer executed pre‑planned transactions on 10/31/2025 under a Rule 10b5‑1 plan. The officer exercised options for 36,542 Class A ordinary shares at $3.80 and 46,000 shares at $8.83, then sold 82,542 shares at a weighted average price of $37.14 (trade range: $36.80–$37.675). Following these transactions, the filing reports 61,324 shares beneficially owned directly. The options exercised were fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) reported an insider transaction by its Chief Financial Officer. On 10/28/2025, the CFO exercised 100 share options at $30.93 and sold 100 Class A Ordinary Shares at $41.00, executed under a Rule 10b5-1 plan dated September 3, 2024. Following these trades, the officer directly owned 31,086 shares and held 19,900 options with an expiration of 09/19/2028. The option was fully vested and exercisable.
Kiniksa Pharmaceuticals International (KNSA) reported a profitable quarter. For Q3 2025, total revenue was $180.855 million, up from $112.214 million a year ago, driven entirely by higher net product revenue from ARCALYST in the U.S. Net income reached $18.435 million versus a loss of $12.693 million last year; diluted EPS was $0.23.
Operating expenses reflected ARCALYST profit sharing with Regeneron, with collaboration expenses at $63.307 million. Cost of goods sold was $20.257 million, R&D $24.166 million, and SG&A $49.104 million. Cash, cash equivalents and short‑term investments totaled $352.102 million as of September 30, 2025, and operating cash flow for the nine months was $84.091 million. Shareholders’ equity increased to $535.383 million from $438.436 million at year‑end.
Year‑to‑date, revenue was $475.437 million (vs. $300.703 million), with net income of $44.806 million (vs. a $34.305 million loss). The company terminated the mavrilimumab license with MedImmune effective May 22, 2025 and mutually terminated the Huadong mavrilimumab agreement; the ARCALYST Huadong agreement remains in place with $31.811 million recorded as non‑current deferred revenue.
Kiniksa Pharmaceuticals International, plc filed a Form 8-K to report that it has released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results in a press release dated October 28, 2025, which is included as Exhibit 99.1. This filing mainly serves to formally furnish that earnings press release to investors and regulators.
Kiniksa Pharmaceuticals International, plc (KNSA) disclosed insider transactions by its Chairman & CEO under a Rule 10b5-1 plan. On 10/20–10/22/2025, the insider exercised 257,969 share options at $3.80 and sold an equal 257,969 Class A Ordinary Shares in brokered trades.
Weighted average sale prices reported include $38.81 (range $38.14–$39.135), $39.32 (range $39.14–$39.55), $38.77 (range $38.49–$39.235), and $38.83 (range $38.495–$39.255). Following these transactions, direct holdings were 111,794 shares. An additional 109,795 shares were held indirectly by The Marina 2016 Irrevocable Trust.
Kiniksa Pharmaceuticals (KNSA) insider transaction: The company’s Chief Accounting Officer exercised multiple vested stock options and sold shares on 10/20/2025 pursuant to a Rule 10b5-1 plan executed on May 24, 2025. Option exercises added 791 shares at $15.50, 6,195 at $12.97, 9,831 at $11.10, 9,831 at $11.97, and 12,787 at $10.76.
The insider then sold 37,255 shares at a weighted average price of $38.72 (trades ranged from $38.14 to $39.135) and 13,235 shares at a weighted average price of $39.31 (trades ranged from $39.145 to $39.57). After these transactions, the insider beneficially owned 27,046 Class A ordinary shares, held directly. The filing notes the options were fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) reported a Form 4 for its COO. On 10/14/2025, the officer exercised 6,500 options at $8.83 and sold 11,815 shares at a $37.65 weighted average and 553 shares at $37.99, executed through multiple trades under a Rule 10b5-1 plan adopted on April 29, 2024. Following these transactions, the officer beneficially owned 28,684 Class A shares directly and 12,500 options remained held. The reported option was fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) officer Michael R. Megna reported changes in beneficial ownership on 10/04/2025. The filing shows 175 restricted share units (RSUs) granted (transaction code M) that convert into Class A ordinary shares and vest over four years with 25% vesting each anniversary of the grant date of 10/04/2021. The reporting person also recorded a sale of 85 Class A ordinary shares (transaction code F) at $38.49, leaving 38,101 shares owned after the sale. Following the RSU grant, total beneficial ownership is reported as 38,186 shares. The form was signed by an attorney-in-fact on 10/08/2025.
Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals International plc (KNSA), exercised 42,000 previously granted options at an exercise price of $17.92 on 09/29/2025, acquiring 42,000 Class A ordinary shares. The option is fully vested and exercisable and has an expiration date of 03/03/2029.
The reporting person sold 42,000 Class A ordinary shares the same day under a 10b5-1 trading plan established April 29, 2024, at a weighted-average sales price of $38.33 per share (trades ranged $37.92–$38.85). After these transactions the reporting person beneficially owned 34,552 Class A ordinary shares.
Kiniksa Pharmaceuticals International, plc (KNSA) filing a Form 144 notifies the intended sale of 42,000 Class A ordinary shares on 09/29/2025 through Charles Schwab & Co., Inc. The shares were acquired the same day via an employee stock option exercise and will be sold in a broker-assisted cashless exercise, with the filing reporting an aggregate market value of $1,609,716 against ~43.47 million shares outstanding.
The filing also discloses prior sales by the same holder, Eben Tessari, totaling 303,865 shares sold across seven transactions from 07/14/2025 to 09/15/2025 for aggregate gross proceeds shown per trade. The notice is a required disclosure under Rule 144 and includes the signer’s representation there is no undisclosed material information.